HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports.
Agenus Trading Up 11.0 %
NASDAQ AGEN opened at $1.86 on Wednesday. The company’s fifty day simple moving average is $3.17 and its 200-day simple moving average is $3.80. Agenus has a 52 week low of $1.65 and a 52 week high of $19.69. The stock has a market cap of $43.63 million, a P/E ratio of -0.17 and a beta of 1.23.
Agenus (NASDAQ:AGEN – Get Free Report) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. On average, research analysts expect that Agenus will post -12.55 EPS for the current fiscal year.
Institutional Trading of Agenus
Agenus Company Profile
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
- Five stocks we like better than Agenus
- The Basics of Support and Resistance
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.